Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rubina Ismail
Institution:
Amgen (United States)
Observed institution:
Amgen (United States)
OpenAlex ID:
A5029047150
Intratumoral Immunotherapy—Update 2019
2019
·
Omid Hamid
, Rubina Ismail
, et al.
·
The Oncologist
·
161
PDF
Observational Study Of Talimogene Laherparepvec Use in the Anti-PD-1 era for Melanoma in the US (COSMUS-2)
2020
·
James Sun
, Brian R Gastman
, et al.
·
Melanoma Management
·
11
Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).
2020
·
Jason Alan Chesney
, Igor Puzanov
, et al.
·
Journal of Clinical Oncology
·
2
Checkpoint inhibitor (CPI) experienced patients (pts) from COSMUS-1: A clinical observational study of talimogene laherparepvec (T-VEC) in United States practice.
2019
·
Matthew Perez
, Thomas Amatruda
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
4
Citation count:
175
H-index:
2
I10-index:
2
Year
Topic
Type
